Form 4: Immunovant CEO Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
Immunovant CEO Peter Salzmann sold shares to cover tax withholding obligations related to the vesting of restricted stock units.
Summary
- Immunovant's CEO, Peter Salzmann, sold shares of common stock on April 17, 2024, to cover tax obligations.
- A total of 26,365 shares were sold at a weighted average price of $28.8, and 7,714 shares were sold at a weighted average price of $29.94.
- Following these transactions, Salzmann directly owns 1,052,879 shares of Immunovant common stock.
- The sales were mandated by Immunovant's policy requiring tax withholding obligations to be funded through 'sell to cover' transactions.
Sentiment
Score: 5
Explanation: The document describes a routine transaction (sell to cover taxes) and doesn't indicate any significant positive or negative sentiment.
Industry Context
Sales of shares to cover tax obligations upon vesting of restricted stock units are a common practice among executives of publicly traded companies.
Key Dates
| Date | Description |
|---|---|
| 04/12/2023 | Date of grant of 243,832 restricted stock units (RSUs). |
| 04/14/2023 | Date of Form 4 filing reporting the grant of RSUs. |
| 04/12/2024 | Vesting date of 60,958 RSUs. |
| 04/17/2024 | Date of stock sales to cover tax withholding obligations. |
| 04/19/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.